Ownership
Private
Employees
~50
Stage
Phase 2
Modalities
Small molecule

Parion Sciences General Information

Developing ENaC inhibitors for pulmonary diseases. Lead compound P-1037 in Phase 2a trials for CF. Established major collaboration with Vertex Pharmaceuticals.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

P-1037
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Parion Sciences's pipeline data

Book a demo

Key Partnerships

Vertex Pharmaceuticals, Cystic Fibrosis Foundation Therapeutics

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Parion Sciences Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Parion Sciences's complete valuation and funding history, request access »